DAX21.294 +0,4%ESt504.961 +0,5%Top 10 Crypto11,98 +5,8%Dow39.187 +2,7%Nas16.300 +2,7%Bitcoin81.872 +7,7%Euro1,1319 -0,5%Öl67,82 +2,0%Gold3.330 -1,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Tesla A1CX3T Rheinmetall 703000 Amazon 906866 RENK RENK73 Novo Nordisk A3EU6F Apple 865985 SAP 716460 Siemens Energy ENER6Y Mercedes-Benz Group (ex Daimler) 710000 Lufthansa 823212 BASF BASF11 Allianz 840400 Microsoft 870747 Volkswagen (VW) vz. 766403
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Trotz Zollstreit: Wall Street schließt sehr fest -- DAX dreht letztlich ins Plus -- VW spricht mit US-Regierung -- Amazon wird bei KI zurückhaltender -- Bayer, SAP, Xiaomi, Rheinmetall, BVB im Fokus
Top News
US-Finanzminister stellt offenbar Einigung mit China in Aussicht US-Finanzminister stellt offenbar Einigung mit China in Aussicht
Tesla-Aktie steigt dennoch: Tesla schlägt sich bei Umsatz und Gewinn schlechter als erwartet Tesla-Aktie steigt dennoch: Tesla schlägt sich bei Umsatz und Gewinn schlechter als erwartet
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Axsome Therapeutics Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
90,74 EUR -1,18 EUR -1,28 %
STU
103,80 USD +0,72 USD +0,70 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.4,37 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2AA7B

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS05464T1043

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAXSM

Axsome Therapeutics Aktien News

DatumMeistgelesen
PR NewswireCLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022
PR NewswireAXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM
PR NewswireAXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR NewswireAXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR NewswireAXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM
PR NewswireCLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022
PR NewswireCLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM
PR NewswireAXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022
PR NewswireROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM
PR NewswireAXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
PR NewswireAxsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM
PR NewswireAXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022
PR NewswireAxsome Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the...
PR NewswireAXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM
PR NewswireAXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR NewswireAXSOME THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the...
PR NewswireAxsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry
PR NewswireShareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Investors to Contact the Firm
PR NewswireAxsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month
PR NewswireJazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics
PR NewswireJazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM
PR NewswireAxsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
PR NewswireAxsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine
PR NewswireAxsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022
Wer­bung

Axsome Therapeutics News

Axsome Therapeutics News: auf dieser Seite finden Sie alle Axsome Therapeutics News und Nachrichten zur Axsome Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Axsome Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Axsome Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.